Navigation Links
Research on Treating Sleep Apnea with Adaptive Servo-ventilation Published in the Journal of the American College of Cardiology (JACC)
Date:3/20/2017

SAN DIEGO, March 20, 2017 /PRNewswire/ -- ResMed (NYSE: RMD) today announced publication of a study in the Journal of the American College of Cardiology (JACC), which investigated whether treatment of moderate to severe sleep-disordered breathing (obstructive or central sleep apnea) with adaptive servo-ventilation (ASV) therapy could improve cardiovascular outcomes in patients who were hospitalized for a sudden worsening of their heart failure (acute decompensated heart failure) over six months.*

"Cardiovascular Outcomes With Minute Ventilation-Targeted Adaptive Servo-Ventilation Therapy in Heart Failure – The CAT-HF Trial" is a multicenter, randomized, controlled Phase II trial funded by ResMed to broaden the understanding of how best to treat diagnosed sleep apnea in patients that also have a particular form of heart failure.

The overall study results were neutral (Wilcoxon p-value = 0.717). However, the study revealed a pre-specified subgroup analysis that showed a statistically significant improvement in the primary endpoint for people with moderate to severe sleep-disordered breathing and heart failure with preserved ejection fraction (HFpEF) (Cox p-value = 0.036). The primary endpoint was cardiovascular outcomes measured as a Global Rank Score that included survival free from cardiovascular hospitalization and change in functional capacity as measured by the six-minute walk distance. The study also assessed changes in functional parameters, arrhythmias, biomarkers, quality of life (QoL), and sleep and breathing.

Leading cardiologists say the improvement for HFpEF patients with sleep apnea signals a potential breakthrough in treatment options for those patients, and call for more research to be done.

"There are no level of evidence 1A guideline recommended therapies specific for HFpEF patients, which accounts for half of all people living with chronic heart failure," said Christopher M. O'Connor, MD, the study's lead investigator, cardiologist and CEO of the Inova Heart and Vascular Institute. "These results from CAT-HF suggest we need to further study the role of whether addressing sleep-disordered breathing can help people who have heart failure with preserved ejection fraction."

"This is another great step forward in understanding the connection between sleep-disordered breathing, heart failure and proper treatment methods," said Dr. Tony DeMaria, a cardiologist from the University of California – San Diego. "We are looking forward to what future heart failure research can tell us about key links to other conditions our patients face."

"Having JACC publish this research is incredibly positive, encouraging others to look deeper into the potential benefits of ASV therapy," said Dr. Carlos Nunez, ResMed Chief Medical Officer. "I hope future studies can further establish these benefits and lead to life-improving treatment recommendations for countless patients with sleep apnea."

About sleep-disordered breathing
Sleep-disordered breathing encompasses a spectrum of breathing problems during sleep. The two most common types of sleep apnea, a condition that results in repetitive pauses in breathing during sleep, are obstructive sleep apnea and central sleep apnea.

Obstructive sleep apnea is a sleep disorder in which the throat muscles relax, block the airways and stop the flow of breath during sleep. Central sleep apnea is a sleep disorder in which the brain does not transmit the "breathe" signal to the muscles that control breathing during sleep. In either situation, the lack of oxygen causes the person to wake up to catch their breath and start breathing again, interrupting continuous sleep. This may occur multiple times in an hour.

About chronic heart failure
Chronic heart failure occurs when the heart does not pump enough blood to meet the needs of the body. When the heart contracts normally but does not relax sufficiently to fill the chamber with enough blood, it is classified as heart failure with preserved ejection fraction. If the heart cannot contract to pump enough blood, it is heart failure with reduced ejection fraction.**

An estimated 26 million people worldwide have heart failure,1 split roughly half-and-half between those with preserved vs. reduced ejection fraction.2 It is believed that sleep-disordered breathing may be found in 69 percent of patients with heart failure with preserved ejection fraction (HFpEF),3 far more commonly than in the general population. People with heart failure often report poor sleep as a symptom.

About the CAT-HF study
The paper was based on the CAT-HF trial, first presented at the European Heart Failure conference in Italy in 2016. CAT-HF was designed to address whether cardiovascular outcomes could be improved with adaptive servo-ventilation (ASV) therapy for either obstructive or central sleep apnea after hospitalization for sudden worsening symptoms for people with both preserved and reduced heart failure. 

CAT-HF is a randomized controlled trial that evaluated whether adding ASV to optimized medical therapy could improve cardiovascular outcomes at six months for people with acute decompensated heart failure (HF) patients compared to optimized medical therapy alone.* Patients were enrolled with a prior or new diagnosis of heart failure after admission to the hospital with sudden worsening of heart failure symptoms. 

About ResMed
ResMed (NYSE: RMD) changes lives with award-winning medical devices and cutting-edge cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 2 million patients remotely monitored every day. Our 5,000-strong team is committed to creating the world's best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries.
ResMed.com | Facebook | Twitter | LinkedIn

* The AirCurve 10 ASV device is indicated for the treatment of patients weighing more than 66 lb (30kg) with obstructive sleep apnea (OSA), central and/or mixed apneas, or periodic breathing.
** ASV therapy is contraindicated in patients with chronic, symptomatic heart failure (NYHA 2-4) with reduced left ventricular ejection fraction (LVEF = 45%) and moderate to severe predominant central sleep apnea. All patients diagnosed with sleep apnea should consult with their physician to determine the most appropriate treatment for their sleep apnea.
1 Ambrosy PA et al. JACC 2014
2 Givertz MM et al. Am J Cardiol 2001
3 Bitter T et al. Eur J Heart Fail 2009

For news media:For investors:Alison Graves

Agnes Lee858-836-6789

858-836-5971news@resmed.com

investorrelations@resmed.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/research-on-treating-sleep-apnea-with-adaptive-servo-ventilation-published-in-the-journal-of-the-american-college-of-cardiology-jacc-300426583.html


'/>"/>
SOURCE ResMed Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Global Photomedicine Market Expected to Reach $5,512 Million by 2022-Allied Market Research
2. Global ENT and Bronchoscopy Devices Market Expected to Reach $24,999 Million by 2022 - Allied Market Research
3. Global Surgical Navigation Systems Market Expected to Reach $963 Million by 2022 - Allied Market Research
4. Advanced Wound Care Market is Expected to Reach $12,454 Million, Globally by 2022 - Allied Market Research
5. Point-of-Care Ultrasound (PoCUS) Device Market, 2022 - Research and Markets
6. Global Photopheresis Products Market Forecast to 2022 - By Therapeutic Area, Product & End User - Research and Markets
7. Medivir Completes Transition of Commercial Products to Fully Focus on Research and Development
8. Medical Ceramics Market is Expected to Reach $5,841 Million by 2022, Globally-Allied Market Research
9. Animal Vaccines Market Expected to Reach $9,159 Million by 2022 - Allied Market Research
10. Research and Markets Has Announced the Launch of Their Novartis Market Research Portal
11. Global $18.51 Billion Spectroscopy Equipment Market Analysis and Trends 2013-2016 - Industry Forecast to 2025 - Research and Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2017)... , May 30, 2017 Hill-Rom Holdings, Inc. (NYSE: ... Annual Global Healthcare Conference on Tuesday, June 13, 2017, in ... Greisch , Hill-Rom,s president and chief executive officer, is scheduled ... live audio webcast can be accessed at http://ir.hill-rom.com/events.cfm . ... of the live event through September 13, 2017. ...
(Date:5/29/2017)...  Cellect Biotechnology Ltd. (NASDAQ: APOP ; TASE: ... functional selection of stem cells, today provided a corporate ... ended March 31 st , 2017. ... first quarter of 2017," said Dr. Shai Yarkoni, Chief ... treatment of the first blood cancer patient in the ...
(Date:5/26/2017)... , May 25, 2017  In response to ... , Direct Relief is working with Pfizer to ... available at no cost to community health centers, free ... providers nationwide. "Pfizer has a long-standing ... medicines and ensuring patient safety through educational activities," said ...
Breaking Medicine Technology:
(Date:6/27/2017)... ... June 27, 2017 , ... Two residents from the ... a video designed to encourage lawmakers to protect Medicaid funding. , The ... Assisted Living (AHCA/NCAL), highlights the story of Chuck and Cathy Schwarz, a couple who ...
(Date:6/27/2017)... York, NY (PRWEB) , ... June 27, 2017 ... ... and marketing experts to contribute to an upcoming case studies guidebook. This guidebook ... her organization. , This book will include articles, case studies and how-to’s that ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... Foundation Fundraiser hygiene symposium in Mystic, CT. Covering the process and maintenance strategies ... experience in these popular periodontal procedures. Drs. Toback and Urbanski practice as experienced ...
(Date:6/27/2017)... ... ... Hammer Strength, the world’s leading performance strength training brand, and the National ... the NBSCA Strength & Conditioning Coach of the Year. , In its 11th ... select the coach who embodies the highest level of excellence and outstanding service to ...
(Date:6/27/2017)... , ... June 27, 2017 , ... ... . Orthodontics is a dental specialty that focuses on treating alignment and occlusion ... improved aesthetics and function. , North Hollywood dentist , Dr. Garemani, ...
Breaking Medicine News(10 mins):